Brain Scientific Inc.’s (BRSF) Rapid Response EE
Post# of 129
(Total Views: 189)
Posted On: 08/05/2021 4:40:10 PM
Brain Scientific Inc.’s (BRSF) Rapid Response EEG Devices Provide Cost-Effective Solution for Neurology Market
- Patented NeuroCap(TM) and NeuroEEG(TM) devices can be used anywhere, ideal for clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes
- Current global market for EEG devices estimated at $956.1 million in 2020, expected to reach $1.6 billion revenue by 2026, CAGR of 8.7% between 2019-2026
Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, focuses on developing cost-effective next-generation medical devices and software with the goal of modernizing and increasing accessibility to brain diagnostics for the rapidly growing neurology market.
Brain Scientific’s patented NeuroCap(TM) and NeuroEEG(TM) devices are positioned to disrupt the expensive EEG market. Company’s Neurotech ecosystem consists of devices that are affordable and sustainable FDA cleared alternatives to the EEG technology seen today. Devices can be used in a wide range of settings, including remote clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes. The NeuroCap – an FDA-cleared disposable pre-gelled EEG headset – features 22 electrodes and 19 active EEG channels that can be used for recording EEGs in nearly any setting. It is complemented by the NeuroEEG, an FDA-cleared portable clinical-grade wireless EEG amplifier that acquires, records, displays and transmits electrical brain activity.
In the future company’s technology will leverage AI and ML technology with an extensive database comprised of normal and abnormal brain data to help detect abnormal activity associated with brain-related diseases like epilepsy, dementia and pre-Alzheimer’s disease. With a cloud-based infrastructure, the devices will be able to collect, aggregate and analyze data, resulting in the rapid development of algorithms that can accurately detect neurological disorders.
The company’s three-stage development process commenced with the first phase in 2018 that resulted in the creation of the NeuroCap and NeuroEEG. The second phase – currently ongoing – is focused on the development of essential cloud-based infrastructure that will be used to transmit data between patients and neurologists. The third and final phase, scheduled for later this year and into 2022 and 2023, will focus on the development of AI and ML processes to increase efficiency, consistency, and accuracy of diagnostic analytics provided by the application.
According to Grandview Research, the current global EEG device market was estimated at $956.1 million in 2020 and is expected to reach $1.6 billion revenue by 2026 with an expected CAGR of 8.7% between 2019-2026 (https://nnw.fm/Is6rl). Currently, over 150 million people are diagnosed globally with epilepsy, dementia and Alzheimer’s disease, and BRSF management expects the market for neurodiagnostic devices to expand in tandem with the growth of neurological disorders throughout the world (https://nnw.fm/ylgfY).
Brain Scientific Inc. aims to address this target market by providing next-generation EEG devices that will leverage AI and ML technology to facilitate the early diagnosis of brain disorders. With a rock-solid commercialization strategy and diverse management team of experts, Brain Scientific is positioned to lead the market in cost-effective portable EEG devices that enable medical professionals to diagnose patients with efficiency, consistency and accuracy in virtually any setting.
For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Patented NeuroCap(TM) and NeuroEEG(TM) devices can be used anywhere, ideal for clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes
- Current global market for EEG devices estimated at $956.1 million in 2020, expected to reach $1.6 billion revenue by 2026, CAGR of 8.7% between 2019-2026
Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, focuses on developing cost-effective next-generation medical devices and software with the goal of modernizing and increasing accessibility to brain diagnostics for the rapidly growing neurology market.
Brain Scientific’s patented NeuroCap(TM) and NeuroEEG(TM) devices are positioned to disrupt the expensive EEG market. Company’s Neurotech ecosystem consists of devices that are affordable and sustainable FDA cleared alternatives to the EEG technology seen today. Devices can be used in a wide range of settings, including remote clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes. The NeuroCap – an FDA-cleared disposable pre-gelled EEG headset – features 22 electrodes and 19 active EEG channels that can be used for recording EEGs in nearly any setting. It is complemented by the NeuroEEG, an FDA-cleared portable clinical-grade wireless EEG amplifier that acquires, records, displays and transmits electrical brain activity.
In the future company’s technology will leverage AI and ML technology with an extensive database comprised of normal and abnormal brain data to help detect abnormal activity associated with brain-related diseases like epilepsy, dementia and pre-Alzheimer’s disease. With a cloud-based infrastructure, the devices will be able to collect, aggregate and analyze data, resulting in the rapid development of algorithms that can accurately detect neurological disorders.
The company’s three-stage development process commenced with the first phase in 2018 that resulted in the creation of the NeuroCap and NeuroEEG. The second phase – currently ongoing – is focused on the development of essential cloud-based infrastructure that will be used to transmit data between patients and neurologists. The third and final phase, scheduled for later this year and into 2022 and 2023, will focus on the development of AI and ML processes to increase efficiency, consistency, and accuracy of diagnostic analytics provided by the application.
According to Grandview Research, the current global EEG device market was estimated at $956.1 million in 2020 and is expected to reach $1.6 billion revenue by 2026 with an expected CAGR of 8.7% between 2019-2026 (https://nnw.fm/Is6rl). Currently, over 150 million people are diagnosed globally with epilepsy, dementia and Alzheimer’s disease, and BRSF management expects the market for neurodiagnostic devices to expand in tandem with the growth of neurological disorders throughout the world (https://nnw.fm/ylgfY).
Brain Scientific Inc. aims to address this target market by providing next-generation EEG devices that will leverage AI and ML technology to facilitate the early diagnosis of brain disorders. With a rock-solid commercialization strategy and diverse management team of experts, Brain Scientific is positioned to lead the market in cost-effective portable EEG devices that enable medical professionals to diagnose patients with efficiency, consistency and accuracy in virtually any setting.
For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)